Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
NCT03392571
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
Study was stopped due to lack of funding
Conditions
Resectable Pancreatic Cancer
Interventions
DRUG:
NGC-Triple regimen
Sponsor
Pancreatic Cancer Research Team
Collaborators
[object Object]